On the other hand, the adjusted or multivariate analysis, based on selected clinical and pathological characteristics, showed that tumor size (T2 vs. T0) (HR 3.12; 95% CI: 1.01–9.59; p = 0.05), histological grade 2 vs. 1 (HR 4.30; 95% CI: 1.01–18.4; p = 0.05), and the biological subtypes luminal B HER2-negative (HR 2.90; 95% CI: 1.55–5.44; p < 0.01) and triple-negative (HR 5.90; 95% CI: 1.90–18.3; p < 0.01), compared to luminal A, were significantly linked to a worse prognosis for breast cancer recurrence (Figure 4, panel A). This evidence concerns the gene ERBB2 and breast cancer.